

SQUARE PHARMACEUTICALS LIMITED

AND ITS SUBSIDIARIES

CONSOLIDATED STATEMENT OF FINANCIAL POSITION (Unaudited)

As At 31 December 2011

	31-12-2011 Taka	31-03-2011 Taka
ASSETS:		
Non-Current Assets:	15,776,877,612	14,066,327,661
Property, Plant and Equipment-Carrying Value	9,384,517,794	8,059,462,294
Capital Work-in-Progress	830,033,552	887,584,197
Investment - Long Term (at Cost)	167,694,430	229,324,380
Investment - Associates Undertaking	4,545,873,792	4,273,562,289
Investment in Marketable Securities (Fair Value)	848,655,498	616,321,955
Preoperating/Preliminary Expenses	102,546	72,546
Current Assets:	7,950,643,779	8,454,124,714
Inventories	3,006,090,411	3,178,959,238
Trade Debtors	646,391,438	1,421,567,342
Advances, Deposits and Prepayments	884,834,410	597,979,121
Short Term Loan	2,038,985,538	2,504,841,900
Margin against BTB Letter of Credits	424,307,023	321,469,720
Cash and Cash Equivalents	950,034,959	429,307,393
TOTAL ASSETS	23,727,521,391	22,520,452,375
SHAREHOLDERS' EQUITY AND LIABILITIES:		
Shareholders' Equity:	18,509,826,015	15,963,712,784
Share Capital	2,648,347,650	1,961,739,000
Share Premium	2,035,465,000	2,035,465,000
General Reserve	105,878,200	105,878,200
Tax Holiday Reserve	1,538,494,137	1,532,954,925
Gain on Marketable Securities (Unrealized)	460,177,836	294,179,676
Retained Earnings	11,721,463,192	10,033,495,983
Non Controlling Interest	6,791,895	5,849,133
Non-Current Liabilities:	1,074,881,733	1,028,511,238
Long Term Loans - Secured	772,016,229	725,645,734
Deffered Tax Liability	302,865,504	302,865,504
Current Liabilities:	4,136,021,748	5,522,379,220
Short Term Bank Loans	1,524,655,879	2,914,113,426
Long Term Loans-Current Portion	529,403,187	518,199,933
Trade Creditors	627,175,791	1,208,102,997
Liabilities for Expenses	108,980,658	90,485,689
Liabilities for Other Finance	1,345,806,233	791,477,175
TOTAL SHAREHOLDERS' EQUITY AND LIABILITIES	23,727,521,391	22,520,452,375

Sd/-
Tapan Chowdhury
Managing Director

Sd/-
Md. Kabir Reza
Chief Financial Officer

SQUARE PHARMACEUTICALS LIMITED

AND ITS SUBSIDIARIES

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (Unaudited) For the 3rd Quarter Ended 31 December 2011

	<i>Nine Months Ended</i>		<i>Third Quarter Ended</i>	
	April-December 2011 Taka	April-December 2010 Taka	October-December 2011 Taka	October-December 2010 Taka
GROSS TURNOVER	16,183,665,627	13,667,680,684	5,358,629,674	4,441,567,616
Less: Value Added Tax	2,108,427,501	1,723,534,070	732,636,080	539,703,162
NET TURNOVER	14,075,238,126	11,944,146,614	4,625,993,594	3,901,864,454
Cost of Goods Sold	(7,794,501,456)	(6,653,643,542)	(2,558,653,064)	(2,206,138,501)
GROSS PROFIT	6,280,736,670	5,290,503,072	2,067,340,530	1,695,725,953
OPERATING EXPENSES:	(2,889,979,504)	(2,374,354,443)	(992,701,928)	(848,698,195)
Selling & Distribution Expenses	(1,943,517,133)	(1,681,270,539)	(661,705,274)	(598,420,740)
Administrative Expenses	(562,615,211)	(509,936,765)	(183,531,168)	(181,344,999)
Financial Expenses	(383,847,160)	(183,147,139)	(147,465,486)	(68,932,456)
PROFIT FROM OPERATIONS	3,390,757,166	2,916,148,629	1,074,638,602	847,027,758
Other Income	327,697,487	292,968,612	106,034,883	132,399,281
PROFIT BEFORE WPPF	3,718,454,653	3,209,117,241	1,180,673,485	979,427,039
Allocation for WPPF	(179,903,735)	(155,312,985)	(56,222,547)	(46,639,383)
PROFIT BEFORE TAX	3,538,550,918	3,053,804,256	1,124,450,938	932,787,656
Provision for Income Tax	(900,806,676)	(672,865,878)	(289,399,632)	(178,354,528)
PROFIT AFTER TAX	2,637,744,242	2,380,938,378	835,051,306	754,433,128
Profit/(Loss) from Associate Undertakings	331,835,291	281,115,638	110,835,612	96,291,476
PROFIT AFTER TAX	2,969,579,533	2,662,054,016	945,886,918	850,724,604
Other Comprehensive Income:				
Gain/(Loss) on Marketable Securities (Unrealized)	165,998,160	260,027,775	188,283,899	146,515,379
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD	3,135,577,693	2,922,081,791	1,134,170,817	997,239,983
Profit Attributable to:				
Owners of the Company	2,968,636,771	2,660,743,963	945,519,512	850,354,913
Non Controlling Interest	942,762	1,310,053	367,406	369,691
	2,969,579,533	2,662,054,016	945,886,918	850,724,604
Total Comprehensive Income Attributable to:				
Owners of the Company	3,134,634,931	2,920,771,738	1,133,803,411	996,870,292
Non Controlling Interest	942,762	1,310,053	367,406	369,691
	3,135,577,693	2,922,081,791	1,134,170,817	997,239,983
Earnings Per Share (EPS)	11.21	10.05	3.57	3.21
Number of Shares used to compute EPS	264,834,760	264,834,760	264,834,760	264,834,760

Sd/-
Tapan Chowdhury
Managing Director

Sd/-
Md. Kabir Reza
Chief Financial Officer

SQUARE PHARMACEUTICALS LIMITED

AND ITS SUBSIDIARIES

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (Unaudited)

For the 3rd Quarter Ended 31 December 2011

	Share Capital Taka	Share Premium Taka	General Reserve Taka	Tax Holiday Reserve Taka	Gain on Marketable Securities (Unrealized) Taka	Retained Earnings Taka	Non Controlling Interest Taka	Total Taka
At 31 March 2011	1,961,739,000	2,035,465,000	105,878,200	1,532,954,925	294,179,676	10,033,495,983	5,849,133	15,969,561,917
Total Comprehensive Income (Apr'11-Dec'11)	-	-	-	-	165,998,160	2,968,636,771	942,762	3,135,577,693
Transfer to Tax Holiday Reserve	-	-	-	5,539,212	-	(5,539,212)	-	-
Cash Dividend (2010-2011)	-	-	-	-	-	(588,521,700)	-	(588,521,700)
Stock Dividend (2010-2011)	686,608,650	-	-	-	-	(686,608,650)	-	-
At 31 December 2011	2,648,347,650	2,035,465,000	105,878,200	1,538,494,137	460,177,836	11,721,463,192	6,791,895	18,516,617,910
At 31 December 2010	1,509,030,000	2,035,465,000	105,878,200	1,248,026,732	426,979,801	7,540,255,536	5,334,713	12,438,655,468

Sd/-
Tapan Chowdhury
Managing Director

Sd/-
Md. Kabir Reza
Chief Financial Officer

SQUARE PHARMACEUTICALS LIMITED

AND ITS SUBSIDIARIES

CONSOLIDATED STATEMENT OF CASH FLOWS (Unaudited)

For the 3rd Quarter Ended 31 December 2011

	April-Decemabr 2011 Taka	April-Decemabr 2010 Taka
Cash Flows From Operating Activities:		
RECEIPTS:		
Collections from Sales	14,886,915,880	11,718,942,206
Others	132,547,141	103,706,196
	15,019,463,021	11,822,648,402
PAYMENTS:		
Purchase of Raw and Packing Materials	6,348,460,603	5,240,264,406
Manufacturing and Operating Expenses	3,613,226,018	2,977,679,161
Financial Expenses	383,847,160	183,147,139
Income Tax	699,151,661	572,162,185
Workers Profit Participation Fund	60,615,528	46,373,760
Others	150,662	3,482,872
	11,105,451,632	9,023,109,523
Net cash provided by operating activities	3,914,011,389	2,799,538,879
Cash Flows From Investing Activities:		
Purchase of Fixed Assets	(1,809,089,578)	(1,089,516,748)
Capital Work-in-Progress	(379,583,809)	(557,079,430)
Preoperating Expenses	(30,000)	(49,546)
Investment	(4,705,434)	(137,013,893)
Short Term Loan	465,856,362	(1,334,599,754)
Interest Received	171,144,762	49,515,786
Dividend Received	83,529,372	77,960,827
Gain against Sale of Marketable Securities	-	114,241,244
Net cash used in investing activities	(1,472,878,325)	(2,876,541,514)
Cash Flows From Financing Activities:		
Long Term Loan Received	418,138,371	84,404,644
Long Term Loan Repaid	(360,564,622)	(326,461,238)
Short Term Bank Loan Increase/(Decrease)	(1,389,457,547)	1,136,321,265
Dividend Paid	(588,521,700)	(528,160,500)
Net cash provided by financing activities	(1,920,405,498)	366,104,171
Increase in Cash and Bank Balances	520,727,566	289,101,536
Cash and Bank Balances at Opening	429,307,393	269,807,801
Cash and Bank Balances at Closing	950,034,959	558,909,337

Sd/-
Tapan Chowdhury
Managing Director

Sd/-
Md. Kabir Reza
Chief Financial Officer

SQUARE PHARMACEUTICALS LIMITED

STATEMENT OF FINANCIAL POSITION (Unaudited)

As At 31 December 2011

	31-12-2011 Taka	31-03-2011 Taka
ASSETS:		
Non-Current Assets:	13,982,194,062	12,422,195,814
Property, Plant and Equipment-Carrying Value	8,434,668,916	6,981,559,781
Capital Work-in-Progress	830,033,552	887,584,197
Investment - Long Term (at Cost)	3,970,121,331	4,031,751,281
Investment in Marketable Securities (Fair Value)	747,370,263	521,300,555
Current Assets:	6,906,163,395	7,022,213,840
Inventories	2,562,446,521	2,541,688,329
Trade Debtors	582,590,689	772,421,345
Advances, Deposits and Prepayments	748,187,622	523,991,079
Short Term Loan	2,167,776,961	2,813,811,332
Cash and Cash Equivalents	845,161,602	370,301,755
TOTAL ASSETS	20,888,357,457	19,444,409,654
SHAREHOLDERS' EQUITY AND LIABILITIES:		
Shareholders' Equity:	15,933,676,590	13,817,708,990
Share Capital	2,648,347,650	1,961,739,000
Share Premium	2,035,465,000	2,035,465,000
General Reserve	105,878,200	105,878,200
Tax Holiday Reserve	1,101,935,237	1,101,935,237
Gain on Marketable Securities (Unrealized)	447,347,024	259,435,115
Retained Earnings	9,594,703,479	8,353,256,438
Non-Current Liabilities:	1,024,881,733	958,511,238
Long Term Loans - Secured	722,016,229	655,645,734
Deferred Tax Liability	302,865,504	302,865,504
Current Liabilities:	3,929,799,134	4,668,189,426
Short Term Bank Loans	1,357,196,409	2,627,483,864
Long Term Loans - Current Portion	489,403,187	478,199,933
Trade Creditors	778,726,804	733,369,218
Liabilities for Expenses	103,609,122	79,499,584
Liabilities for Other Finance	1,200,863,612	749,636,827
TOTAL SHAREHOLDERS' EQUITY AND LIABILITIES	20,888,357,457	19,444,409,654

Sd/-
Tapan Chowdhury
Managing Director

Sd/-
Md. Kabir Reza
Chief Financial Officer

SQUARE PHARMACEUTICALS LIMITED

STATEMENT OF COMPREHENSIVE INCOME (Unaudited) For the 3rd Quarter Ended 31 December 2011

	<i>Nine Months Ended</i>		<i>Third Quarter Ended</i>	
	April-December 2011 Taka	April-December 2010 Taka	October-December 2011 Taka	October-December 2010 Taka
GROSS TURNOVER	13,748,965,352	11,494,123,124	4,648,129,535	3,807,414,566
Less: Value Added Tax	1,880,419,096	1,524,608,926	651,564,732	476,243,958
NET TURNOVER	11,868,546,256	9,969,514,198	3,996,564,803	3,331,170,608
COST OF GOODS SOLD	(6,276,633,747)	(5,277,916,346)	(2,180,030,870)	(1,821,101,939)
GROSS PROFIT	5,591,912,509	4,691,597,852	1,816,533,933	1,510,068,669
OPERATING EXPENSES:	(2,763,054,022)	(2,267,658,417)	(950,412,359)	(810,226,652)
Selling & Distribution Expenses	(1,861,004,865)	(1,608,686,588)	(633,196,403)	(573,231,940)
Administrative Expenses	(545,453,947)	(497,448,901)	(179,342,787)	(175,946,995)
Financial Expenses	(356,595,210)	(161,522,928)	(137,873,169)	(61,047,717)
PROFIT FROM OPERATIONS	2,828,858,487	2,423,939,435	866,121,574	699,842,017
Other Income	654,283,940	574,239,174	196,998,245	205,350,275
PROFIT BEFORE WPPF	3,483,142,427	2,998,178,609	1,063,119,819	905,192,292
Allocation for WPPF	(165,863,925)	(142,770,410)	(50,624,753)	(43,104,395)
PROFIT BEFORE TAX	3,317,278,502	2,855,408,199	1,012,495,066	862,087,897
Provision for Income Tax	(800,701,111)	(672,865,878)	(247,645,877)	(178,354,528)
PROFIT AFTER TAX	2,516,577,391	2,182,542,321	764,849,189	683,733,369
Other Comprehensive Income:				
Gain on Marketable Securities (Unrealized)	187,911,909	209,450,188	169,150,303	266,274,155
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD	2,704,489,300	2,391,992,509	933,999,492	950,007,524
Earnings Per Share (EPS)	9.50	8.24	2.89	2.58
Number of Shares used to compute EPS	264,834,760	264,834,760	264,834,760	264,834,760

Sd/-
Tapan Chowdhury
Managing Director

Sd/-
Md. Kabir Reza
Chief Financial Officer

SQUARE PHARMACEUTICALS LIMITED

STATEMENT OF CHANGES IN EQUITY (Unaudited) For the 3rd Quarter Ended 31 December 2011

	Share Capital Taka	Share Premium Taka	General Reserve Taka	Tax Holiday Reserve Taka	Gain on Marketable Securities (Unrealized) Taka	Retained Earnings Taka	Total Taka
At 31 March 2011	1,961,739,000	2,035,465,000	105,878,200	1,101,935,237	259,435,115	8,353,256,438	13,817,708,990
Total Comprehensive Income (Apr'11-Dec'11)	-	-	-	-	187,911,909	2,516,577,391	2,704,489,300
Cash Dividend (2010-2011)	-	-	-	-	-	(588,521,700)	(588,521,700)
Stock Dividend (2010-2011)	686,608,650	-	-	-	-	(686,608,650)	-
At 31 December 2011	2,648,347,650	2,035,465,000	105,878,200	1,101,935,237	447,347,024	9,594,703,479	15,933,676,590
At 31 December 2010	1,961,739,000	2,035,465,000	105,878,200	1,101,935,237	244,762,969	8,003,744,209	13,453,524,615

Sd/-
Tapan Chowdhur,
Managing Director

Sd/-
Md. Kabir Reza
Chief Financial Officer

SQUARE PHARMACEUTICALS LIMITED

STATEMENT OF CASH FLOWS (Unaudited) For the 3rd Quarter Ended 31 December 2011

	April-December 2011 Taka	April-December 2010 Taka
Cash Flows From Operating Activities:		
RECEIPTS:		
Collections from Sales	12,108,415,685	9,931,274,810
Others	378,039,528	324,635,643
	12,486,455,213	10,255,910,453
PAYMENTS:		
Purchase of Raw and Packing Materials	4,589,072,976	4,050,969,445
Manufacturing and Operating Expenses	3,344,059,962	2,679,684,373
Financial Expenses	356,595,210	161,522,928
Income Tax	678,565,506	558,559,682
Workers Profit Participation Fund	59,681,788	45,856,360
Others	150,662	3,475,439
	9,028,126,104	7,500,068,227
Net cash provided by operating activities	3,458,329,109	2,755,842,226
Cash Flows From Investing Activities:		
Purchase of Fixed Assets	(1,768,400,980)	(934,232,703)
Capital Work-in-Progress	(379,583,809)	(557,079,430)
Investment	23,472,150	(77,013,893)
Short Term Loan	646,034,371	(1,492,863,055)
Interest Received	192,715,040	57,490,460
Dividend Received	83,529,372	77,871,827
Gain against Sale of Marketable Securities	-	114,241,244
Net cash used in investing activities	(1,202,233,856)	(2,811,585,550)
Cash Flows From Financing Activities:		
Long Term Loan Received	418,138,371	84,404,644
Long Term Loan Repaid	(340,564,622)	(296,461,238)
Short Term Bank Loan Increase/(Decrease)	(1,270,287,455)	1,075,731,592
Dividend Paid	(588,521,700)	(528,160,500)
Net cash (used)/provided by financing activities	(1,781,235,406)	335,514,498
Increase in Cash and Cash Equivalents	474,859,847	279,771,174
Cash and Cash Equivalents at the Opening	370,301,755	258,727,695
Cash and Cash Equivalents at the Closing	845,161,602	538,498,869

Sd/-
Tapan Chowdhury
Managing Director

Sd/-
Md. Kabir Reza
Chief Financial Officer